Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effectiveness and Efficacy of the Combination of Pharmacotherapy With the Two New Recovery-oriented Programs, RECOVERYTRSGR (Treatment Resistant Schizophrenia) and RECOVERYTRSBDGR (Treatment Resistant Bipolar Disorder)

NCT07047651 is registered in ClinicalTrials.gov with Dr. Stavroula Rakitzi as lead sponsor.

NCT NCT07047651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07047651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effectiveness and Efficacy of the Combination of Pharmacotherapy With the Two New Recovery-oriented Programs, RECOVERYTRSGR (Treatment Resistant Schizophrenia) and RECOVERYTRSBDGR (Treatment Resistant Bipolar Disorder)
Lead sponsor
Dr. Stavroula Rakitzi
Phase
Phase 4
Overall status
Active, not recruiting
Start date
June 4, 2025
Completion date
December 20, 2027
Enrollment
84 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant bipolar disorder, treatment resistant schizophrenia